Korea Clinical Trial Approvals (MFDS) - Sponsors, Phases, Sites avatar

Korea Clinical Trial Approvals (MFDS) - Sponsors, Phases, Sites

Pricing

from $10.00 / 1,000 clinical trials

Go to Apify Store
Korea Clinical Trial Approvals (MFDS) - Sponsors, Phases, Sites

Korea Clinical Trial Approvals (MFDS) - Sponsors, Phases, Sites

Newly approved drug clinical trials in South Korea from MFDS, in English: sponsor, developer, phase, indication, design, enrollment, trial sites. Search by sponsor, drug, phase or site.

Pricing

from $10.00 / 1,000 clinical trials

Rating

0.0

(0)

Developer

KH C

KH C

Maintained by Community

Actor stats

0

Bookmarked

2

Total users

1

Monthly active users

6 days ago

Last modified

Features

Limited permissions

Share

Korea Clinical Trial Approvals (MFDS) in English

Every drug clinical trial approved in South Korea by the Ministry of Food and Drug Safety (MFDS, 식품의약품안전처), as clean JSON with English titles, sponsors, developers, phases, indications and trial sites:

  • New trial approvals, newest first: MFDS publishes approvals within days, and this Actor returns them in one call.
  • One record per trial, joined from two MFDS datasets: the trial plan (title, phase, status, indication, objective, design, target enrollment in total and in Korea, dates, endpoints) and the trial list (sponsor and all Korean trial sites).
  • Search by sponsor (e.g. IQVIA, Novartis), original developer (Pfizer, Hanmi), product or code (ABBV-400), active ingredient, keyword, site (Asan Medical Center), phase, therapeutic area, status, multinational vs Korea-only, developer country and first-in-human.
  • Trial sites mode: the 233 MFDS-designated clinical trial sites, with designation date, IRB type, region and how many trials each site has run (total since 2012 and in the last 12 months).
  • Monitoring: schedule it daily with "only new" and receive each new approval once.

Who uses this

  • Pharma and biotech business development: see which companies are starting Phase 1–3 programs in Korea, with which molecule, in which indication, before results or press releases.
  • Competitive intelligence: follow a competitor's or a molecule's trial activity in Korea (e.g. every new obesity or KRAS trial, every Chinese-originated first-in-human trial).
  • CROs and site networks: spot new multinational trials and their sponsors and CROs, find the busiest hospitals for a phase or area, and track new site designations.
  • Licensing and investors: screen Korean biotechs by pipeline activity (code, phase, area, enrollment).
  • AI agents and apps that need Korean trial data through the Apify API or MCP.

Example output

Trial (trialIds: ["202600897"]), long Korean text shortened:

{
"type": "clinical_trial",
"trialId": "202600897",
"approvalDate": "2026-11-12",
"titleEn": "A Phase 3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects with Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Expressing c-Met Protein Level Above a Defined Cutoff",
"titleEnSource": "MFDS",
"titleKo": "이전에 치료를 받은 EGFR 야생형, 국소 진행성/전이성 비편평 비소세포폐암이 ...",
"phase": "Phase 3",
"status": "Approved, not yet recruiting",
"sponsorEn": "AbbVie Korea Ltd.",
"sponsorKo": "한국애브비(주)",
"developerEn": "AbbVie Inc.",
"productName": "ABBV-400",
"therapeuticArea": "Oncology",
"therapeuticSubArea": "Targeted therapy",
"conditionEn": "Non-squamous Non-small Cell Lung Cancer",
"conditionKo": "비편평 비소세포폐암",
"objectiveEn": "Primary objectives are as follows:\n• To evaluate the efficacy of telisotuzumab adizutecan compared with standard therapy, measured by OR per OS and/or BICR assessment. ...",
"purpose": "Marketing authorization",
"developmentOrigin": "Developed outside Korea",
"scope": "Multinational",
"design": { "type": "Parallel", "randomized": true, "blinding": "Open", "arms": 2 },
"firstInHuman": false,
"activeComparator": true,
"placeboControlled": false,
"comparatorKo": "라무시루맙,도세탁셀",
"dosageFormsEn": ["Lyophilized powder for solution for injection"],
"targetEnrollment": 660,
"targetEnrollmentKorea": 30,
"plannedPeriod": { "from": "2027-02", "to": "2031-04" },
"primaryEndpointsKo": "• RECIST 버전 1.1에 따른 BICR 평가에 기반한 OR\n• OS",
"sites": [
{ "nameEn": "Korea University Guro Hospital", "nameKo": "고려대학교 의과대학 부속 구로병원" },
{ "nameEn": "Samsung Medical Center", "nameKo": "삼성서울병원" },
{ "nameEn": "National Cancer Center Korea", "nameKo": "국립암센터" },
{ "nameEn": "Severance Hospital, Yonsei University College of Medicine", "nameKo": "연세대학교의과대학세브란스병원" }
],
"siteCount": 7,
"sponsorRegion": "Seoul",
"detailLevel": "full",
"source": "https://www.data.go.kr/data/15090589/openapi.do"
}

Trial site (mode: sites, site: Samsung):

{
"type": "trial_site",
"siteId": "19",
"nameEn": "Samsung Medical Center",
"nameKo": "삼성서울병원",
"designationDate": "1997-03-11",
"irbType": "Own IRB",
"addressKo": "서울특별시 강남구",
"region": "Seoul",
"trialCount": 3723,
"trialsLast12Months": 303,
"latestTrialApprovalDate": "2026-11-12"
}

Each trial also carries dosing period, first/last subject enrolled and last-visit dates (when reported), secondary endpoints, administration method, dosage form in Korean, the original developer's country, and the latest amendment approval date.

Input examples

Newest approvals (default):

{ "mode": "trials", "maxItems": 10 }

All Phase 1 trials at a hospital this year:

{ "site": "Asan Medical Center", "phases": ["phase1"], "since": "2026-01-01", "maxItems": 100 }

A company's trials (sponsor = the applicant in Korea, often the local subsidiary or the CRO):

{ "sponsor": "IQVIA", "since": "2026-01-01", "maxItems": 200 }

Competitive watch, daily schedule:

{ "keyword": "obesity", "onlyNew": true, "monitorName": "obesity-watch", "maxItems": 50 }

Chinese-originated first-in-human oncology trials, multinational:

{ "therapeuticAreas": ["Oncology"], "developerCountry": "China", "firstInHumanOnly": true, "scope": "multinational", "maxItems": 20 }

Trial sites with trial counts:

{ "mode": "sites", "region": "Seoul", "maxItems": 100 }

Pricing

Pay per result, nothing else:

ResultEventPrice
Clinical trialclinical-trial$0.01
Trial sitetrial-site$0.003

English titles, names and translations are included.

Data and English

  • Source: Ministry of Food and Drug Safety (MFDS) via data.go.kr (datasets 15090589 clinical trial plan details, 15056835 clinical trial information, 15058129 clinical trial sites), license: no usage restrictions (이용허락범위 제한 없음). This Actor is not affiliated with the MFDS.
  • titleEn is the official English title filed with MFDS when there is one (titleEnSource: "MFDS", about 70% of trials); otherwise it is translated by AI ("AI").
  • Phases, statuses, areas, design, dosage forms and countries are mapped to English with fixed tables. Sponsor, developer and site names come from a reviewed English name table covering every name seen so far; new names, conditions, objectives and Korean product/ingredient names are translated by AI (Claude) when "Translate missing English" is on. Korean originals are always included.

FAQ

How current is it? MFDS updates the datasets in near real time; new approvals usually appear within a few days of approval.

What is covered? Full trial details for approvals since January 2019 (about 8,300 trials, roughly 900–1,300 per year). Approvals from 2012 to 2018 (about 6,000) come from the trial list with basic fields only (detailLevel: "basic": title, sponsor, phase, product, sites). Medical device trials are not included.

Sponsor vs developer? sponsor is the applicant that filed the trial in Korea (a local subsidiary, a Korean company, a hospital for investigator-initiated trials, or a CRO acting for a foreign sponsor). developer is the company that owns the investigational product.

Searching English drug names? Sponsors register ingredients in English or Korean. ingredient: "semaglutide" finds the English entries; add the Korean name (세마글루티드) for the rest, or use keyword, which also matches English titles.

Why does a site show 0 trials? Trial counts match the site's name in the trial list exactly; a few sites are listed under a different name there.

Limits? maxItems caps the results. Searches without a product, ingredient or developer scan approvals newest first and stop when enough results are found.